CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0649 (clinicaltrials.gov NCT No: NCT01217229)
Title:A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:PLX3397
Study Status:Terminated
Study Description:The main goal of this clinical research study is to learn if the study drug
PLX3397 can help to control Hodgkin lymphoma. The safety of this study drug
and how the study drug affects your body will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:PLX3397
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Plexxikon Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults